Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Screen-and-treat program to prevent spontaneous preterm birth
ACTRN12617001593325Phase 3Terminated
- Sponsor
- The University of Western Australia
- Start
- Oct 2018
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin, clindamycin and Canesflor in preterm birth (2 arms), sponsored by The University of Western Australia. Primary endpoint: Spontaneous preterm birth rate <37 weeks. Started Oct 2018; status: terminated.
02
Drugs
azithromycinclindamycinCanesflor
03
Conditions
preterm birth
Beyond the preview
Go deeper on ACTRN12617001593325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001593325.